SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

BARTON BRADFORD

(Last)

(First)

(Middle)

C/O ALLIQUA BIOMEDICAL, INC.

2150 CABOT BOULEVARD WEST

(Street)

LANGHORNE

19047

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/29/2014

3. Issuer Name and Ticker or Trading Symbol
Alliqua BioMedical, Inc. [ ALQA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	15,210⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽²⁾	05/10/2023	Common Stock	54,855⁽¹⁾	$4.38⁽¹⁾	D
Stock Option (right to buy)	⁽²⁾	05/10/2023	Common Stock	54,855⁽¹⁾	$5.47⁽¹⁾	D
Stock Option (right to buy)	⁽²⁾	05/10/2023	Common Stock	54,855⁽¹⁾	$6.56⁽¹⁾	D
Stock Option (right to buy)	⁽²⁾	05/10/2023	Common Stock	54,855⁽¹⁾	$8.75⁽¹⁾	D
Stock Option (right to buy)	⁽²⁾	05/10/2023	Common Stock	54,855⁽¹⁾	$10.94⁽¹⁾	D
Stock Option (right to buy)	⁽³⁾	03/06/2024	Common Stock	70,000	$9	D
Warrant (right to buy)	06/28/2013	06/28/2018	Common Stock	9,877⁽¹⁾	$4.24⁽¹⁾	D

Explanation of Responses:

1. The number of shares and prices reported in this Form 4 reflect a 1-for-43.75 reverse stock split of the common stock of the Issuer that occurred on November 18, 2013.

2. Represents a single option granted on May 10, 2013 in five separate tranches. Each tranche vests in three equal annual installments, with one-third (1/3rd) vesting on May 10, 2013, May 17, 2014 and May 17, 2015, subject to Mr. Barton's continued service with the Issuer on the applicable vesting date.

3. The option vests in three equal annual installments, with one-third (1/3rd) vesting on March 6, 2015, 2016 and 2017, subject to Mr. Barton's continued service with the Issuer on the applicable vesting date.

	/s/Bradford Barton	09/08/2014
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.